GC Green Cross Presents Immunoglobulin Thrombosis Research at ISTH 2025

Suggests Potential to Reduce Viscosity-Related Risks with Room Temperature Administration

GC Green Cross announced on July 17 that its U.S. subsidiary, GC Biopharma USA, presented research results on the viscosity of immunoglobulin products at the 2025 International Society on Thrombosis and Haemostasis (ISTH) held in New Jersey, USA.

Aliglo. GC Green Cross

Immunoglobulin products are used to treat immune disorders and are known to increase blood viscosity after administration, which can raise the risk of thromboembolism. In this presentation, the viscosity of five commercially available immunoglobulin products was measured under various temperature conditions ranging from 4°C to 25°C. All products showed a tendency for viscosity to decrease as the temperature increased. Accordingly, it was suggested that administering at room temperature (25°C) could potentially reduce viscosity-related risks.

This study quantitatively compared the viscosity of products by applying a standardized measurement method for immunoglobulin concentration. The research team emphasized that physical properties of immunoglobulin products, such as viscosity and purity, could serve as important safety indicators to consider when selecting products for patients at high risk of thrombosis.

Susan Struthers, Head of Clinical Education at GC Biopharma USA, who presented the data, stated, "Although these are preliminary results, there may be differences in viscosity between products, so further research is needed." She added, "This could provide clinically important clues for selecting the most suitable product for patients at high risk of thrombosis."

The study was presented in a poster session under the title "A Comparative Study of the Viscosity of Commercially Available Immunoglobulin Products." The analysis included immunoglobulin products distributed in the United States, including Aliglo from GC Green Cross.

Aliglo is a 10% immunoglobulin product approved by the U.S. FDA for the treatment of primary immunodeficiency (PI) in adults aged 17 and older. With 50 years of expertise in plasma fractionation product manufacturing, GC Green Cross currently supplies a variety of products to more than 50 countries.